Real-World Cardiovascular Outcomes of GLP-1 Receptor Agonists in Women With Type 2 Diabetes and Breast Cancer - PubMed
3 days ago
- #breast cancer
- #GLP-1 receptor agonists
- #cardiovascular outcomes
- The study examines cardiovascular (CV) benefits of GLP-1 receptor agonists (GLP-1 RA) in women with type 2 diabetes (T2D) and breast cancer.
- Primary objective was to compare major adverse cardiovascular events (MACE) incidence between GLP-1 RA and non-GLP-1 RA diabetes medications.
- Retrospective study included 19,608 matched patients per cohort (mean age 64 years), with GLP-1 RA showing lower MACE incidence (10.6% vs. 13.4%).
- GLP-1 RA use was associated with significant reductions in individual MACE endpoints, ischemic heart disease, end-stage renal disease, and all-cause mortality (61.6% relative risk reduction).
- Pancreatitis incidence was similar between groups, but cholelithiasis was significantly lower with GLP-1 RA therapy.
- Findings suggest potential CV benefits of GLP-1 RA in female breast cancer survivors with T2D, though randomized trials are needed for confirmation.